What are the opening hours?

Monday 9:30am - 5:30pm Tuesday 9:30am - 5:30pm Wednesday 9:30am - 5:30pm Thursday 9:30am - 5:30pm Friday 9:30am - 5:30pm

Cancer Research & Treatment Fund, Inc.

Home
United States
New York, NY
Cancer Research & Treatment Fund, Inc.

The official page of Cancer Research & Treatment Fund. Please follow us to receive our latest news. In 2012, CR&T began funding the Richard T. Silver.

The Cancer Research and Treatment Fund (CR&T) is a driving force in cancer research and treatment. Founded in 1968, we are a not-for-profit fund that is committed to the belief that advances in blood cancer research lead to important breakthroughs, and a better understanding of the biology and treatment of all forms of cancer. In 2000, CR&T and the generosity of donors were instrumental in the establishment of the Center for the Study of Leukemia and Myeloproliferative Neoplasms at Weill Cornell Medical College, a leading institution for cancer research. More recently, we have been involved with the breakthrough discoveries of Gleevec and now the JAK2 enzyme cancer marker . Silver Myeloproliferative Neoplasm Center at Weil Cornell Medical College, the successor to the Center for the Study of Leukemia and Myelproliferative Neoplasms at Weill Cornel Medical College. The center was dedicated in a special ceremony on February 18, 2014, and will serve as a translational research and treatment center, engaging in cutting edge discoveries surrounding MPNs. CR&T played a pivotal role in establishing the Silver MPN Center. In addition to contributing a $3.7 million gift, the Center is named after CR&T’s founder, Dr. Richard T. Dr. Andrew Schaefer, former Chairman of the Department of Medicine at Weill Cornell Medical College, has been appointed as the Center’s Director. We have achieved these successes by aggressively pursuing biological, pharmacological and molecular solutions to understand cancer, and to design drugs and diagnostic tools based on new knowledge—providing critical resources for a multidisciplinary approach that offers the greatest promise against all forms of cancer. For more than three decades, CR&T has been a major source of financial support for researchers on the frontlines of clinical cancer research at Weill Medical College of Cornell University, located at New York-Presbyterian Hospital. We have also awarded grants for research at Johns Hopkins University Medical Center, MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center.

02/20/2026

Big congratulations to Aleksei Martianov, PhD, postdoctoral fellow in the Bergmeier Lab at the University of North Carolina at Chapel Hill, on receiving the inaugural ASH Richard T. Silver, MD Abstract Achievement Award for Myeloproliferative Neoplasms! 🎉

Dr. Martianov delivered an oral presentation at the recent ASH Annual Meeting, highlighting his abstract:

“Platelet Priming in MPN Triggers Prothrombotic Intermediate Affinity State in αIIbβ3 Integrin.”

This prestigious recognition reflects the impact of his research in advancing our understanding of myeloproliferative neoplasms and thrombosis.

Read the abstract here:
https://doi.org/10.1182/blood-2025-415

Please join us in celebrating this outstanding achievement!

02/17/2026

Every discovery starts with support.

Your contribution helps CR&T fund critical research aimed at improving outcomes for blood cancer patients.
💙 Support the mission: https://www.crt.org/donate/

02/06/2026

“The molecular management of classic myeloproliferative neoplasm” — A 2025 review detailing how genomic tools & next-generation sequencing are transforming diagnosis & management of classic MPNs.

Background Whole-genome sequencing has enabled the development of a wide range of analytical tools to search for abnormalities associated with tumors. As classic myeloproliferative neoplasms (MPNs) are associated with genomic alterations in hematopoietic stem cells, the World Health Organization (WH...

02/04/2026

Cancer touches millions of lives — and behind every diagnosis is a person, a family, a story.

This World Cancer Day, CR&T reaffirms our commitment to care, innovation, and standing beside those who need it most. 💙

At CR&T, we stand with patients, families, caregivers, and healthcare professionals in the global fight against cancer. Together, we keep pushing for better outcomes, better access, and better hope.

01/28/2026

A global leader in MPN research and care 🧬

CR&T proudly founded the Richard T. Silver, MD MPN Center at Weill Cornell Medicine, now one of the world’s leading centers dedicated to myeloproliferative neoplasms.

📊 Published research. Global recognition. Real patient impact.

👉 Learn more about the Silver MPN Center on our website https://www.crt.org/the-silver-mpn-center/

01/19/2026

Dr. Martin Luther King Jr. taught us that everyone can serve. Today, we honor his legacy through action and compassion.

01/15/2026

For more than 57 years, CR&T has believed in one powerful idea:
Investing in blood cancer research leads to breakthroughs for all cancers.
What gives you hope in the fight against cancer? 💙

Tell us in the comments—and learn how CR&T is helping turn hope into cures on our website.

01/14/2026

CR&T-supported research is featured in a new Weill Cornell Medicine Research Matters video spotlighting efforts to personalize pancreatic cancer treatment. Translational research, fueled by CR&T support, is helping move discoveries closer to patient care.

Dr. Despina Siolas, assistant professor of medicine at Weill Cornell Medicine, is working to personalize treatment for pancreatic cancer and develop new therapeutic regimens that save more patient lives.

01/10/2026

Every year, CR&T hosts the International Patient Symposium on MPNs, sharing the latest research and treatment updates from leading experts—now available in our video library.
🎥 Check out past symposium presentations at https://www.crt.org/mpn-patient-symposium-videos/

MPN Patient Symposium Videos Every year, CR&T hosts the Richard T. Silver, MD International Patient Symposium on Myeloproliferative Neoplasms (MPNs). This full-day educational event takes place in New York City, and is an opportunity for patients and caregivers to learn about the latest developments...

01/09/2026

Research supported by CR&T was highlighted in The Queens Gazette, featuring Dr. Despina Siolas' work to advance personalized treatment approaches for pancreatic cancer. The piece underscores the translational impact made possible through CR&T’s support.

“Research matters in personalizing pancreatic cancer treatment,” says Despina Siolas, MD, PhD, a physician scientist and Assistant Professor of Medicine at Weill Cornell Medicine. Her message is at the center of a recent episode of Research Matters, a video series highlighting innovative resea...

01/06/2026

Cancer research never stands still—and neither do we.

CR&T’s Research Updates share the latest discoveries, scientific publications, and insights from leading physician-scientists.

📖 Stay informed. Stay inspired.
👉 Visit our website at crt.org to read the latest updates.

For more than 50 years, the Cancer Research and Treatment Fund (CR&T) has worked to advance the treatment of various types of blood cancers including MPNs.

01/01/2026

As we welcome the New Year, we look ahead with renewed determination and hope 🎆
In 2026 and beyond, CR&T remains committed to advancing innovative cancer research and supporting the scientists working toward cures.

✨ Thank you for being part of our journey!

Address

500 E 77th Street, Ste 1001
New York, NY
10162

Opening Hours

Monday	9:30am - 5:30pm
Tuesday	9:30am - 5:30pm
Wednesday	9:30am - 5:30pm
Thursday	9:30am - 5:30pm
Friday	9:30am - 5:30pm

Website

http://www.crt.org/

Alerts

Be the first to know and let us send you an email when Cancer Research & Treatment Fund, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cancer Research & Treatment Fund, Inc.:

Shortcuts

Featured

Magnus Wellness
16 E 40th Street, Fl 4

Want your practice to be the top-listed Clinic in New York?

Our Story

The Cancer Research and Treatment Fund (CR&T) is a driving force in cancer research and treatment. Founded in 1968, we are a not-for-profit fund that is committed to the belief that advances in blood cancer research lead to important breakthroughs, and a better understanding of the biology and treatment of all forms of cancer. In 2000, CR&T and the generosity of donors were instrumental in the establishment of the Center for the Study of Leukemia and Myeloproliferative Neoplasms at Weill Cornell Medical College, a leading institution for cancer research. More recently, we have been involved with the breakthrough discoveries of Gleevec and now the JAK2 enzyme cancer marker . In 2012, CR&T began funding the Richard T. Silver Myeloproliferative Neoplasm Center at Weil Cornell Medical College, the successor to the Center for the Study of Leukemia and Myelproliferative Neoplasms at Weill Cornell Medical College. The center was dedicated in a special ceremony on February 18, 2014, and serves as a translational research and treatment center, engaging in cutting edge discoveries surrounding MPNs. CR&T played a pivotal role in establishing the Silver MPN Center. In addition to contributing a $3.7 million gift, the Center is named after CR&T’s founder, Dr. Richard T. Silver. Dr. Andrew Schafer, former Chairman of the Department of Medicine at Weill Cornell Medical College, has been appointed as the Center’s Director. We have achieved these successes by aggressively pursuing biological, pharmacological and molecular solutions to understand cancer, and to design drugs and diagnostic tools based on new knowledge—providing critical resources for a multidisciplinary approach that offers the greatest promise against all forms of cancer. CR&T will mark its 50th Anniversary in 2018. For nearly 50 years, the organization has been a major source of financial support for researchers on the frontlines of clinical cancer research at Weill Medical College of Cornell University, located at New York-Presbyterian Hospital. We have also awarded grants for research at Johns Hopkins University Medical Center, MD Anderson Cancer Center, and Memorial Sloan-Kettering Cancer Center.